Hypericin and 5-aminolevulinic acid-induced protoporphyrin IX induce enhanced phototoxicity in human endometrial cancer cells with non-coherent white light. 2009

Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
Central Laboratory, Triemli Hospital, Zurich, Switzerland. Xiaoye.Schneider@triemli.stzh.ch

BACKGROUND The in vitro experiments described in this study were aimed at exploring a synergistic effect between 5-aminolevulinic acid (5-ALA) induced protoporphyrin IX (PpIX) and hypericin. In a previous study, enhanced phototoxicity was observed in a patient during a clinical study on 5-ALA-based photodynamic tumor localization of breast cancer. This patient ingested a hypericin containing plant extract in parallel to orally applied 5-ALA. METHODS Human endometrial cancer cells (HEC-1A) were treated with 0.5mM of 5-ALA and 60 nM of hypericin, either separately or combined. Colony formation was assessed after illumination of the cells with both red (635 nm) and white light (400-800 nm) at a dose of 2.5 J/cm(2). Porphyrin metabolites were quantified by HPLC in cells treated with photosensitizers without subsequent illumination. RESULTS After white light illumination, cells treated with a combination of 5-ALA and hypericin had a significant reduction in colony formation compared with cells treated with 5-ALA only. No significantly enhanced toxicity was found with red light and the 5-ALA plus hypericin combination. In addition, cells treated with both 5-ALA and hypericin tended to produce more PpIX than cells treated with 5-ALA only. CONCLUSIONS This study demonstrated that treatment of endometrial cancer cells with both 5-ALA and hypericin followed by illumination with white light induced a significantly higher phototoxicity as revealed by colony formation. This setting which generated an in vitro effect similar to the patient's situation, might be applied in the future as an affordable and effective photodynamic therapy (PDT) modality.

UI MeSH Term Description Entries
D008027 Light That portion of the electromagnetic spectrum in the visible, ultraviolet, and infrared range. Light, Visible,Photoradiation,Radiation, Visible,Visible Radiation,Photoradiations,Radiations, Visible,Visible Light,Visible Radiations
D010569 Perylene A 20-carbon dibenz(de,kl)anthracene that can be viewed as a naphthalene fused to a phenalene or as dinaphthalene. It is used as fluorescent lipid probe in the cytochemistry of membranes and is a polycyclic hydrocarbon pollutant in soil and water. Derivatives may be carcinogenic. Perilene,Peri-Dinaphthalene,Peri Dinaphthalene
D011524 Protoporphyrins Porphyrins with four methyl, two vinyl, and two propionic acid side chains attached to the pyrrole rings. Protoporphyrin IX occurs in hemoglobin, myoglobin, and most of the cytochromes.
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000622 Aminolevulinic Acid A compound produced from succinyl-CoA and GLYCINE as an intermediate in heme synthesis. It is used as a PHOTOCHEMOTHERAPY for actinic KERATOSIS. 5-Amino Levulinic Acid,5-Aminolaevulinate,5-Aminolevulinate,Aminolevulinic Acid Hydrochloride,Delta-Aminolevulinic Acid,Levulan,5 Amino Levulinic Acid,5 Aminolaevulinate,5 Aminolevulinate,Acid Hydrochloride, Aminolevulinic,Acid, 5-Amino Levulinic,Acid, Aminolevulinic,Acid, Delta-Aminolevulinic,Delta Aminolevulinic Acid,Hydrochloride, Aminolevulinic Acid,Levulinic Acid, 5-Amino
D000873 Anthracenes A group of compounds with three aromatic rings joined in linear arrangement.
D016889 Endometrial Neoplasms Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells. Cancer of Endometrium,Endometrial Cancer,Endometrial Carcinoma,Cancer of the Endometrium,Carcinoma of Endometrium,Endometrium Cancer,Neoplasms, Endometrial,Cancer, Endometrial,Cancer, Endometrium,Cancers, Endometrial,Cancers, Endometrium,Carcinoma, Endometrial,Carcinomas, Endometrial,Endometrial Cancers,Endometrial Carcinomas,Endometrial Neoplasm,Endometrium Cancers,Endometrium Carcinoma,Endometrium Carcinomas,Neoplasm, Endometrial
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
July 1996, Biochemical and biophysical research communications,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
September 2007, Journal of photochemistry and photobiology. B, Biology,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
January 1997, International journal of cancer,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
October 2016, Acta neurochirurgica,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
September 1997, International journal of cancer,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
January 2012, PloS one,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
July 2012, Journal of neuro-oncology,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
February 2001, Acta pharmacologica Sinica,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
June 2012, Oncology reports,
Xiaoye Schneider-Yin, and Aida Kurmanaviciene, and Marion Roth, and Malgorzata Roos, and André Fedier, and Elisabeth I Minder, and Heinrich Walt
October 1997, Journal of photochemistry and photobiology. B, Biology,
Copied contents to your clipboard!